Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 43 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... MOST POPULAR A New Era of Early Cancer Detection With Blood Test May... September 11, 2022 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... May 28, 2025 The right combination for early detection August 4, 2021 EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Load more HOT NEWS Easing Concerns about Giving Research Study Participants Their Genetic Test Results Summer Sun Safety Tips FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... De qué manera el seguimiento de los síntomas mejora la atención...
